Health and Fitness Health and Fitness
Fri, February 27, 2009
[ 01:00 PM ] - Market Wire
Rexahn Pharmaceuticals Receives Notice from NYSE Alternext US LLC
[ 12:30 PM ] - Market Wire
Tenet Healthcare Corporation Announces Completion of Exchange Offer
[ 12:30 PM ] - Market Wire
Nanobac Pharmaceuticals: Nanobac Message to Shareholders
[ 09:41 AM ] - Market Wire
Amador Gold Corp.: Amador Drills Gold and Nickel-Copper Targets at Loveland Project
[ 07:17 AM ] - Market Wire
Schaeffer's Street Stories: AstraZeneca plc Plunges on FDA Concerns Regarding Seroquel Approval
[ 06:24 AM ] - Market Wire
UnitedHealth Group to Open New Service Center in Harlingen, Texas
[ 06:00 AM ] - Market Wire
Edwards Lifesciences : Edwards Lifesciences' Chai .. nd CEO Revises Existing 10b5-1 Stock Trading Plan
[ 05:58 AM ] - Market Wire
Healthways Participates in New NCQA Wellness & Health Promotion Accreditation Program
[ 05:15 AM ] - Market Wire
Cougar Biotechnology Announces Presentation of Po .. etate) Phase II Data at ASCO 2009 Genitourinary C
[ 05:00 AM ] - Market Wire
Trinity Biotech: Trinity Biotech plc to Announce Year End Results
[ 04:30 AM ] - Market Wire
Health Net Federal Services Wins Department of Ve .. d Outpatient Clinic Contract in Durango, Colorado
[ 04:30 AM ] - Market Wire
Cell Genesys Announces Final Results from Phase 3 .. Program of GVAX Immunotherapy for Prostate Cancer
[ 04:00 AM ] - Market Wire
CONMED Corporation: CONMED Corporation Sets Annual Meeting Date
[ 03:32 AM ] - Market Wire
OSI Pharmaceuticals Response to Initial Non-Final .. Office Action by U.S. Patent and Trademark Office
[ 03:30 AM ] - Market Wire
Emergent BioSolutions to Webcast Presentation at .. Health Care Conference on Tuesday, March 17, 2009
[ 03:30 AM ] - Market Wire
AMAG Pharmaceuticals, Inc. Reports Financial Resu .. for the Quarter and Year Ended December 31, 2008
[ 03:00 AM ] - Market Wire
Celldex Reports Fourth Quarter and Fiscal 2008 Financial Results
[ 03:00 AM ] - Market Wire
BIOLASE Technology, Inc.: BIOLASE Launches New Wa .. se(R) MD Turbo(TM) All-Tissue Dental Laser System
[ 02:30 AM ] - Market Wire
EPIX Pharmaceuticals Announces Resignation of Chief Business Officer
[ 02:00 AM ] - Market Wire
Panacos Announces Voluntary Decision to Delist Co .. aq and Terminate SEC Registration of Common Stock
[ 12:00 AM ] - Market Wire
Alexion Joins NORD and EURORDIS in Supporting the Goals of Rare Disease Day
Thu, February 26, 2009
[ 02:36 PM ] - Market Wire
Salix Announces FDA Complete Response Letter for METOZOLV" ODT
[ 02:30 PM ] - Market Wire
Data Published in The Lancet Show Fampridine-SR I .. Walking Ability in People with Multiple Sclerosis
[ 01:59 PM ] - Market Wire
DexCom Schedules Fourth Quarter and Full Year 200 .. ngs Release and Conference Call for March 5, 2009
[ 01:39 PM ] - Market Wire
FDA Clears First Quick-Med Product
[ 01:25 PM ] - Market Wire
CIGNA Issues Podcast Providing Details and Commen .. n Health Care Portion of President Obama's Budget
[ 01:05 PM ] - Market Wire
Theravance, Inc.: Theravance Receives Complete Re .. in New Drug Application for the Treatment of cSSS
[ 12:53 PM ] - Market Wire
BioTime's Subsidiary Enters Agreement Adding New .. mbryonic Stem Cell Lines to Its Product Portfolio
[ 12:40 PM ] - Market Wire
Synta Suspends Elesclomol SYMMETRYSM Trial in Metastatic Melanoma
[ 12:30 PM ] - Market Wire
Dynavax to Report Fourth Quarter and Year End 2008 Financial Results on March 2, 2009

Dynavax to Report Fourth Quarter and Year End 2008 Financial Results on March 2, 2009


Published on 2009-02-26 14:54:52, Last Modified on 2009-02-26 14:55:19 - Market Wire
  Print publication without navigation


BERKELEY, Calif.--([ BUSINESS WIRE ])--Dynavax Technologies Corporation (Nasdaq:DVAX) announced today that it plans to report fourth quarter and year end 2008 financial results on Monday, March 2, 2009 before the market opens.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of novel Toll-like Receptor (TLR) based product candidates. Based on Dynavax's proprietary technologies, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax has partnerships with leading pharmaceutical companies such as GlaxoSmithKline, AstraZeneca AB, and Novartis as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health. For more information visit [ www.dynavax.com ].

Contributing Sources